The investor has taken an "all-in" position in Hims & Hers Health ($HIMS), purchasing 2,316 shares at an average cost of $26.72, with the stock recently rising to $30.40 in overnight markets. The bullish thesis cites high consumer demand for peptides and a 34% short interest ahead of earnings on Monday, 5/11, though risks include a Novo Nordisk lawsuit and margin compression from distributing branded Wegovy. The investor previously sold a position in IREN at $61.85 but remains bullish and intends to swing trade back into the asset following the $HIMS earnings report.